TOLERABILITY
Clinical trials for TOLERABILITY explained in plain language.
Never miss a new study
Get alerted when new TOLERABILITY trials appear
Sign up with your email to follow new studies for TOLERABILITY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First human test for new Graves' disease drug begins
Disease control Recruiting nowThis early-stage study is testing the safety of a new medication called GenSci098 for people with Graves' disease, an autoimmune condition that causes overactive thyroid. Researchers will give 24 participants increasing doses of the drug to check for side effects and see how the …
Matched conditions: TOLERABILITY
Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 23:11 UTC
-
New cancer drug enters human testing for advanced solid tumors
Disease control Recruiting nowThis early-stage study is testing a new drug called HY07121 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose, check for side effects, and see if the drug shows any early signs of shrinking tumors. The…
Matched conditions: TOLERABILITY
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New eye disease drug enters human testing phase
Disease control Recruiting nowThis early-stage study aims to test the safety and side effects of a new injectable drug called GenSci098 in people with thyroid eye disease. Researchers will give increasing doses to 76 participants to see how their bodies handle the medication and monitor for any problems. The …
Matched conditions: TOLERABILITY
Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New hope for tough cancers: testing a targeted drug
Disease control Recruiting nowThis study is testing a new drug, HYP-2090PTSA, for people with advanced solid tumors that have a specific genetic change called a KRAS mutation. The first part aims to find a safe and effective dose. The second part will explore how well the drug works for certain cancers with a…
Matched conditions: TOLERABILITY
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New pill targets tough cancers: first human trial begins
Disease control Recruiting nowThis early-stage trial is testing a new oral medication called IPG7236 in adults with advanced solid tumors that have stopped responding to standard treatments. Researchers will first determine safe dosage levels and then expand to specific cancer types including kidney, breast, …
Matched conditions: TOLERABILITY
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
First human test of new inhaled compound begins
Knowledge-focused Recruiting nowThis is the first study in humans to test a new inhaled compound called RCS-21. The main goal is to check if it is safe and how the body processes it. Healthy volunteers will inhale a single dose and be closely monitored for side effects. This is an early, basic safety study, not…
Matched conditions: TOLERABILITY
Phase: PHASE1 • Sponsor: RNATICS GmbH • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC